Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

onvansertib (PCM-075)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Cardiff Oncology, Nerviano Medical Sciences

Drug class:

PLK1 inhibitor

Related drugs:

‹

›

KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	bevacizumab + PCM-075 Sensitive: C2 – Inclusion Criteria bevacizumab + PCM-075 Sensitive : C2	bevacizumab + PCM-075 Sensitive: C2 – Inclusion Criteria bevacizumab + PCM-075 Sensitive : C2
AR-V7 mutation	Prostate Cancer	AR-V7 mutation	Prostate Cancer	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3
AR T878A	Prostate Cancer	AR T878A	Prostate Cancer	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
MYC amplification	Medulloblastoma	MYC amplification	Medulloblastoma	PCM-075 Sensitive: D – Preclinical PCM-075 Sensitive : D	PCM-075 Sensitive: D – Preclinical PCM-075 Sensitive : D
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib + PCM-075 Sensitive: D – Preclinical olaparib + PCM-075 Sensitive : D	olaparib + PCM-075 Sensitive: D – Preclinical olaparib + PCM-075 Sensitive : D
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	PCM-075 Sensitive: D – Preclinical PCM-075 Sensitive : D	PCM-075 Sensitive: D – Preclinical PCM-075 Sensitive : D
PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer	PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer	alpelisib + PCM-075 Sensitive: D – Preclinical alpelisib + PCM-075 Sensitive : D	alpelisib + PCM-075 Sensitive: D – Preclinical alpelisib + PCM-075 Sensitive : D